Sanofi targets Dupixent peak sales of over 13 bln euros (updated)

IGM Biosciences

29/03/2022 06:11

(Adds detail on partnership with IGM in last paragraph)
    PARIS, March 29 (Reuters) - French healthcare group Sanofi
 SASY.PA , which lagged rivals in the race for COVID-19
vaccines, raised on Tuesday its peak sales target for
eczema-treatment product Dupixent to more than 13 billion euros
($14.3 billion).
    "This new ambition does not include potential for additional
sales ambition upgrade from chronic obstructive pulmonary
disease (COPD), with pivotal readouts anticipated in 2023,"
Sanofi said in a statement.
    This month, analysts at investment bank JP Morgan had said
they expected Sanofi to raise its peak sales guidance for 
Dupixent to about $15 billion.  urn:newsml:reuters.com:*:nL5N2VB2U9
    Sanofi is working with British partner GlaxoSmithKline
 GSK.L  to develop a COVID-19 vaccine.  urn:newsml:reuters.com:*:nL1N2UY160
    Sanofi also announced on Tuesday a partnership with U.S
company IGM Biosciences in the field of treatments for oncology,
immunology and inflammation.  urn:newsml:reuters.com:*:nGNE4QS0P6
    ($1=0.9096 euros)

 (Reporting by Sudip Kar-Gupta; Editing by Clarence Fernandez
and Jacqueline Wong)
 ((sudip.kargupta@thomsonreuters.com; +33 1 49 49 53 84;))